Table 4.
Predictors of PFS
| Univariable | Multivariable | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | aHR | 95% CI | p-value | |
| Age > 60 yr | 0.72 | 0.56–0.99 | 0.046 | |||
| Male | 0.81 | 0.52–1.27 | 0.364 | |||
| PIVKA II > 250 mAU/mL | 1.30 | 0.97–1.75 | 0.080 | |||
| AFP > 200 ng/mL | 1.85 | 1.39–2.47 | < 0.001 | 1.79 | 1.33–2.40 | < 0.001 |
| Total bilirubin | 1.08 | 1.00–1.17 | 0.063 | |||
| Albumin | 1.03 | 0.80–1.34 | 0.798 | |||
| ALT | 1.00 | 1.00–1.01 | 0.129 | |||
| AST | 1.00 | 1.00–1.00 | 0.183 | |||
| PT | 1.48 | 0.92–2.39 | 0.109 | |||
| Presence of ascites | 1.23 | 0.89–1.69 | 0.212 | |||
| ECOG 1 (vs 0) | 1.70 | 1.25–2.33 | 0.001 | 1.61 | 1.18–2.21 | 0.003 |
| Child B,C (vs A) | 1.18 | 0.85–1.65 | 0.330 | |||
| BCLC stage C,D (vs B) | 1.35 | 0.85–2.14 | 0.209 | |||
| Tumor size | 1.00 | 1.00–1.00 | 0.060 | |||
| Extrahepatic metastasis | 1.10 | 0.81–1.49 | 0.559 | |||
| Portal vein thrombosis | 1.07 | 0.81–1.43 | 0.626 | |||
| Biliary invasion | 1.34 | 0.76–2.36 | 0.307 | |||
| Lenvatinib (vs sorafenib) | 0.73 | 0.52–1.04 | 0.078 | 0.77 | 0.55–1.11 | 0.159 |
| Previous anti-HCC treatment | 0.84 | 0.58–1.22 | 0.356 | |||
Multivariable analysis was performed using variables with p value under 0.05 at univariable analysis
HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; PIVKA, protein induced by vitamin K absence or antagonists-II; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer